Payment overview · 2025
General Payments
$19.76
1 reported records · 1 companies
Healthcare provider profile · identity verified
Nathan E Rider, NURSE PRACTITIONER
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · LUCASVILLE, OH · NPI 1669782413
Verified facts
What the public records show
CMS Open Payments records show Nathan E Rider, NURSE PRACTITIONER received $19.76 in general payments during 2025 across 1 reported records.
ABBVIE INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.76 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $19.76 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 672 | 108 |
| Atorvastatin Calcium | Atorvastatin Calcium | 505 | 92 |
| Lisinopril | Lisinopril | 438 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 381 | 60 |
| Omeprazole | Omeprazole | 308 | 47 |
| Metformin Hcl | Metformin Hcl | 299 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 285 | 49 |
| Gabapentin | Gabapentin | 268 | 42 |
| Potassium Chloride | Potassium Chloride | 218 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 200 | 36 |
| Furosemide | Furosemide | 199 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 183 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 181 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 176 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 163 | 34 |
| Ozempic | Semaglutide | 159 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 150 | 35 |
| Jardiance | Empagliflozin | 143 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 143 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 133 | 28 |
| Tramadol Hcl | Tramadol Hcl | 131 | 20 |
| Allopurinol | Allopurinol | 128 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 124 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 18 |
| Simvastatin | Simvastatin | 113 | 17 |
| Losartan Potassium | Losartan Potassium | 111 | 21 |
| Sertraline Hcl | Sertraline Hcl | 109 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 107 | 24 |
| Carvedilol | Carvedilol | 103 | 19 |
| Lorazepam | Lorazepam | 102 | 16 |
| Montelukast Sodium | Montelukast Sodium | 102 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 99 | 34 |
| Trazodone Hcl | Trazodone Hcl | 96 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 95 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 84 | 11 |
| Valsartan | Valsartan | 84 | 11 |
| Mounjaro | Tirzepatide | 76 | 11 |
| Ondansetron Odt | Ondansetron | 75 | 24 |
| Meclizine Hcl | Meclizine Hcl | 68 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 67 | suppressed |
| Ezetimibe | Ezetimibe | 66 | 12 |
| Meloxicam | Meloxicam | 66 | 13 |
| Ibuprofen | Ibuprofen | 64 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 11 |
| Fenofibrate | Fenofibrate | 62 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 12 |
| Januvia | Sitagliptin Phosphate | 59 | suppressed |
| Methylprednisolone | Methylprednisolone | 59 | 46 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 56 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | suppressed |
| Famotidine | Famotidine | 52 | 12 |
| Metformin Hcl Er | Metformin Hcl | 52 | suppressed |
| Tradjenta | Linagliptin | 50 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | suppressed |
| Levetiracetam | Levetiracetam | 49 | suppressed |
| Pregabalin | Pregabalin | 49 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 49 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 12 |
| Sucralfate | Sucralfate | 44 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Bupropion Xl | Bupropion Hcl | 43 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 42 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Lovastatin | Lovastatin | 38 | suppressed |
| Finasteride | Finasteride | 36 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 35 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 35 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Eliquis | Apixaban | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Rybelsus | Semaglutide | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Acyclovir | Acyclovir | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 23 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 24 |
| Glimepiride | Glimepiride | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Admelog Solostar | Insulin Lispro | 16 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Epinephrine | Epinephrine | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 13 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 13 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Savella | Milnacipran Hcl | 11 | suppressed |
| Tacrolimus | Tacrolimus | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $19.76 · 1 records | ABBVIE INC. | VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error